Clinical Trial Update: Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab. [Phase 2]

View source ↗

Summary

Phase II pilot study evaluating Visudyne photodynamic therapy at low fluence combined with bevacizumab for age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Bevacizumab (bevacizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: University of British Columbia | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED